GlaxoSmithKline PLC and Pfizer Inc.'s planned consumer health joint venture will have one less product to manage as GSK continues offloading non-core brands with the sale of the Keri line to skin care product marketer Crown Laboratories Inc.
The April 30 deal didn't make GSK's presentation for its 2019 first-quarter results a day later. The UK big pharma's...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?